GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours

GARNET study demonstrated objective response rate of 41.6% across dMMR solid tumours